

26th October, 2020 – For immediate release

### **Medcan Australia participates in CMOS (Cannabinoid Medicine Observational Study)**

Medcan Australia (Medcan) is pleased to announce its participation in CMOS.

CMOS is a cannabis medicine observational study that will be run in collaboration with GP's and specialists around Australia. This study aims to recruit 20,000 Australian patients undergoing treatment with medicinal cannabis.

CMOS will benefit participating clinicians, and their patients, by providing insight into medicinal cannabis prescribing and treatment practices from clinics around Australia participating in CMOS. Insights will be provided in the form of de-identified aggregated data reports including information on product dosing/categories being prescribed, patient reported outcomes (PROs) and adverse events reported by study participants, to be released to participating clinics on a quarterly basis. This data will provide a useful resource for clinicians who may be prescribing medicinal cannabis products and wish to gain better insight into the current Australian prescribing landscape.

Prescribing doctors will have access to MEDCAN products and will collect safety and efficacy data for a range of indications including fibromyalgia, chronic pain syndromes, PTSD, epilepsy and other mental health and neurological conditions.

Further information and participation criteria can be requested at:

<https://medcanaustralia.com.au/contact/>

#### **Comments from Craig Cochran – Managing Director, Founder, Medcan Australia:**

Medcan Australia Founder and CEO, Craig Cochran said: "Medcan Australia are very excited to be a part of the CMOS study. Studies like CMOS are extremely important to build credible data around medicinal cannabis products and patient responses for various indications. As a leader in the Australian medicinal cannabis industry, Medcan Australia is proud to support the advancement of medicinal cannabis research both locally and internationally"

#### **Background**

**Medcan Australia** was founded in 2016 and was one of the first Australian companies to be licensed by the Office of Drug Control (ODC) to cultivate and produce Medicinal Cannabis, manufacture Medicinal Cannabis products and import and export Medicinal Cannabis products. The company was founded with a single vision to provide Australian patients with high quality, fair priced Medicinal Cannabis products.

Medcan have a dedicated Cultivation, Production, Manufacture and Pharmaceutical wholesaling facility located in Brisbane Australia. Medcan currently import a range of TGO93 compliant MEDCAN branded products for supply to Australian patients.

**For Further Information please contact:**



Gareth Ball  
+61414860512  
1800 633 226  
Po Box 4579, Springfield, QLD, Australia, 4300  
[gareth@medcanaustralia.com.au](mailto:gareth@medcanaustralia.com.au)  
[www.medcanaustralia.com.au](http://www.medcanaustralia.com.au)